01
概述
Protamax为前列腺组织衍生的复合短肽制剂，归类于Khavinson生物调节肽体系。
02
药理与机制
通过组织特异性短肽序列影响相关组织的基因表达与细胞分化模式。
03
研究方向
R.01
前列腺组织衍生肽复合物
前列腺组织生物学、男性内分泌与组织特异性老化研究中的工具肽组合。
04
结构信息
短肽混合物，分子量低，针对组织特异性研究。
氨基酸序列
Short-peptide mixture (proprietary)
仅供科研用途。不构成医疗建议，不用于诊断或治疗。
← 返回列表条目 · LZH-017
lyophilized
Composite bioregulator · 复合生物调节
Protamax
前列腺组织衍生肽复合物
技术数据LZH-017
- 代号
- Composite bioregulator
- 半衰期
- Short plasma; transcriptional residence
- 研究给药途径
- SC / sublingual (research)
- 分子靶点
- Tissue-specific transcriptional modulation
- 发现 / 披露
- Khavinson bioregulator school
- 目标纯度
- ≥ 98%
- 建议储存
- −20°C 避光，复溶后 2~8°C
别名
Prostate peptide bioregulator complex
外观
White lyophilized powder
溶解性
Water soluble
氨基酸序列
Short-peptide mixture (proprietary)
FIG. 201Analytical Lab
Identity, purity and main-peak area are checked by reversed-phase HPLC against an in-house reference standard for this sequence. The chromatogram you see on the certificate of analysis is generated at this exact bench, by the analysts who release the batch.
FIG. 202Scale-up Operations
When a sequence moves from milligram research lots to multi-gram research supply, the same chemistry is transferred onto jacketed stainless reactors. Temperature, agitation and reagent equivalents are logged in real time so that the larger batch matches the analytical fingerprint of the small one.